About Z2
Antibodies & recombinant proteins
Focused scientific consultancy within the biologics CMC pathway
Z2 Biopharma Solutions provides focused scientific consultancy in mammalian cell line development (CLD) and upstream process development (UPD) within the broader biologics CMC (Chemistry, Manufacturing and Controls) framework, supporting antibody and recombinant protein development programmes from host/vector and cell line strategy through process development, scale-up and technology-transfer readiness.
We support biotechnology programmes across the development journey – from early-stage concepts and proof-of-concept (PoC) studies through active bioprocess development towards manufacturing readiness. Z2 also supports investors, funders and strategic partners through independent technical due diligence, helping assess scientific validity, technical maturity, scalability, development risks and the value potential of emerging technologies and biologics programmes.
From discovery to developable process
An integrated approach
More than 18 years of experience across academia, biotechnology and biopharmaceutical development underpin an integrated approach to cell line development, cell culture media development and upstream process development.
- Monoclonal antibodies & recombinant proteins
- mRNA therapeutics & emerging platforms
A distinctive, industrial perspective
Experience spanning fundamental research, translational science, global CDMO development and commercial bioprocessing allows promising laboratory science to be viewed through an industrial development lens – identifying what needs to change as a concept progresses towards a reproducible, scalable and manufacturable process.
- Fed-batch & perfusion development
- Process intensification & scale-up
Broader bioprocess support
Z2's direct focus is cell line and upstream development. A panel of experienced consultants brings wider expertise where a programme needs it – downstream, analytical/bioanalytical and manufacturing interfaces.
Small teams now carry most of the pipeline
Emerging biotechs now own two-thirds of the drug pipeline, yet few have a senior CMC lead in-house – and CMC is the one risk a sponsor controls.
67%
The newcomers
Emerging biopharma's share of the global R&D pipeline in 2022 – double its 2002 share.1
1 in 15
Slipping approvals
Drugs entering Phase I that now reach approval, down from 1 in 10.2
74%
Manufacturing problems
Of FDA rejection letters issued 2020–2024 cited quality or manufacturing (CMC) deficiencies.3
1 IQVIA Institute, Global Trends in R&D 2023. 2 Hay et al., Nat Biotechnol 2014; BIO, Biomedtracker & Amplion 2016; BIO, Informa & QLS 2021; Citeline Biomedtracker 2024. 3 Pharmaceutical Technology, CMC and analytical gaps in CRLs, July 2026. Read the full briefing
Scientific and regulatory insight, end to end
Z2 Biopharma Solutions is a focused cell line development and upstream CMC consultancy supporting antibody and recombinant protein development programmes from host/vector and cell line strategy through process development, scale-up, technology transfer and manufacturing readiness. We combine scientific and regulatory insight with technical due diligence, laboratory and capability establishment, biosafety readiness and investment/funding support, complemented by broader bioprocess expertise from Z2 consultants where required.
Cell Line Development
Host, vector and selection-system strategy, clone screening and selection, stability and clonality – planned for the molecule and its CMC path.
Cell Culture Media Development
Media and feed optimisation, raw-material strategy and metabolic interpretation to lift growth, titre and consistency.
Upstream Process Development
Shake-flask and bioreactor development, fed-batch and perfusion, seeding and feeding strategies and process intensification.
Process Characterisation & Optimisation
QbD, DoE, critical process parameters, robustness and qualified scale-down models.
Scale-Up & Technology Transfer
Transfer strategy, CMC and process-transfer packages, site gap analysis, comparability and receiving-site readiness.
CMC & Development Strategy
CMC planning, IND/BLA documentation support, technical due diligence and investment readiness.
AI/ML & Bioprocess Data Analytics
Machine learning, multivariate analysis, PAT/Raman and predictive modelling to design smarter experiments.
Development Capability Building
Laboratory set-up, workflows, SOPs, qualification, biosafety/GMO compliance and technical team mentoring.
Let's talk about your programme
Whether you are designing a CLD programme, stuck on an upstream process, preparing for technology transfer, or assessing a biologics asset before you commit.
Call Anil